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SUMMARY 
Bleeding oesophageal varices still remain a common cause of significant morbidity and 
mortality in Kenya and is the leading cause of upper gastrointestinal haemorrhage as seen at 
Kenyatta National Hospital, Nairobi. We report on our experiences in the management of 
oesophageal varices using injection sclerotherapy. The study site was the Centre for Clinical 
Research, Kenya Medical Research Institute (KEMRI).  Records from structured reporting 
on procedures and findings during oesophageal variceal injection sclerotherapy were 
reviewed. All the patients with portal hypertension and previous history of acute variceal 
blood who underwent endoscopic injection sclerotherapy between August 1998 and May 
2001 in the endoscopy unit, KEMRI, had between 2 and 8 sessions of sclerotherapy with 10-
15 ml of 5% ethanolamine oleate during each session.  The injection sclerotherapy was done 
under sedation and pharyngeal local anaesthesia.  This was followed by regular surveillance 
endoscopic examination at 1,3,6 months then yearly. A total of 112 patients underwent 
vericeal injection sclerotherapy.  Male: Female of 2:2:1 and mean age was 32.8 ± 3.3 years. 
Eighty-five (75.9%) of the patients received at least 4 sessions of injections sclerotherapy.  
82.4% of those who received sclerotherapy upto 4 sessions had regression of varices and 
15% of patients’ required more than 6 sessions. The report concludes that variceal injection 
sclerotherapy is a useful method of treating oesophageal varices and can be performed on an 
out patient basis. 
[Afr J Health Sci. 2007; 14:216-218] 
 
Introduction 
Bleeding oesophageal varices are a leading cause of 
haematemesis in many African countries [1-2]. A 
study done by Lule and colleagues in 1990-91 
showed that bleeding oesophageal varices was the 
leading cause of haematemesis at Kenyatta National 
Hospital [1]. Management of portal hypertension 
with significant oesophageal varices can be divided 
into 2 broad categories namely pharmacological and 
non-pharmacological. The non-pharmacological 
category can further be divided into surgical and non-
surgical. The non-surgical category includes 
endoscopic variceal injection sclerotherapy 
endoscopic variceal banding and transjuglar 
intrahepatic porto systemic shunting (TIPS) [3].  
Reports by Jani, Kiire and Omar show that both 
variceal banding and injection sclerotherapy were 
effective in reducing or obliterating oesophageal 
varices thereby reducing the risk of variceal bleed in 
patients with portal hypertension [3-5]. At KEMRI, 
endoscopic injection sclerotherapy of oesophageal 





hypertension constitutes about one third of the 
workload in the endoscopy unit. 
 
Objective 
Reports on our experiences in the management of 
oesophageal varices in-patients with portal 
hypertension using endoscopic injection 
sclerotherapy on out-patient basis. 
 
Methodology 
This is a report on all patients with portal 
hypertension and previous history of acute variceal 
bleed who underwent endoscopic injection 
sclerotherapy between August 1998 and May 2001 in 
the endoscopy unit, Kenya Medical Research 
Institute. 
       All patients with portal hypertension who came 
for injection sclerotherapy had a history of at least an 
episode of hematemesis. Most patients were 
outpatients, only a few were inpatients mainly from 
Kenyatta National Hospital.  All patients had large 
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bluish varices on commencement of sclerotherapy.  
The protocol of sclerotherapy was as follows: 
 informed consent was obtained before the procedure, 
each patient had local pharyngeal anesthesia using 
xyclocaine spray after which pethidine (50-100 mg), 
Buscopan (hyosane bytylbromide) (20 mg) and 
Dormican (Midazolum) (2.5 – 5 mg) were given 
intravenously; the sclerosant used was 5% 
ethanolamine oleate.  Two mililiters (ml) of scerosant 
was injected into each varix or paravariceal and a 
total of 10-15 ml was used during each session.  The 
patient was allowed a few hours to recover from 
sedation before discharge on buscopan tablets 20 mg 
three times for a few days, paracetamol and anti-acids 
or H2 receptor antagonists to be taken orally when in 
pain.  The injection was done weekly for the first 4 
sessions.  Thereafter the injection was given 2 weekly 
for the 5th and 6th sessions and subsequent sessions 
until obliteration of varices was achieved.  After 
complete obliteration of the varices, the patients were 
followed up by surveillance check endoscopy at 1 
month, 3 months, 6 months then yearly.  Any varices 
that may reform were detected at surveillance and 
were injected with sclerosant. 
   
Results 
A total of 112 patients underwent endoscopic 
injection sclerotherapy between October 1998 and 
May 2001.  Of these, 76 were males and 36 females.  
The age range was 5 to 71 years.  Age distribution is 
as shown in Table 1. 
 
               Table 1: Age distribution 
 















































               Male: female = 2:1; Mean age for the study population was 32.8± 3.3. 
 
              Table 2 : Injection sclerotherapy sessions given 
Number of 
sessions 
1 2 3 4 5 6 7 8 9 10 
 
Patients 
9 10 8 13 12 45 8 2 3 1 
 
 
All the patients who received more than 2 injection 
sclerotherapy sessions had marked reduction in 
variceal size. Eight five (75.9)% of the patients 
received at least 4 sessions and their varices greatly 
reduced in size by the 4th session. 70 (82.4%) of those 
who received more than 4 sessions had complete 
obliteration of the varices by the 6th session.  15 of 
the patients required more than 6 sessions as shown 
in Table 2: - 
         Patients were scheduled to get 6 injection 
sclerotherapy sessions. Some did not compete the 6 
sessions. The patients were not stratified according to 
the aetiology of portal hypertension and response to 
treatment and age. However, it was observed that 
those patients with poor response to treatment had 
severe liver decompensation and were the ones who 
required more than six sessions. All patients had 
retrosternal  chest pain after injection for a day or two 
and required an antispasmodic and paracetamol for 
pain relief.  Ninety percent of the patients had 
odynophagia for about two days after injection but 
this cleared spontaneously.  Injection site ulceration 
also occurred in 80% of patients but ulcers healed on 




Injection sclerotherapy is often carried out on 
inpatients for fear of bleeding within 24 hrs after 
injection.  We report on injection sclerotherapy 
carried out on 112 outpatients.  The usual way of 
giving injection sclerotherapy to inpatients is 
expensive to most patients since they have to pay for 
the admission. The main reason for admission has 
been fear of bleeding immediately and within 24 
hours after the injection. Hence the need to observe 
the patient closely in hospital. We did not have any 
major problem with bleeding after sclerotherapy.  
However, two patients bled in between sessions and 
required admission for blood transfusion. One of 
these patients bled in between sessions and required 
admission for blood transfusion. One of these 
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patients had severe liver disease.  It was found out 
that at least 6 sessions of injection sclerotherapy were 
required to achieve variceal obliteration as seen in 
82.4% of our cases who received more than 4 
sessions. Each session of injection sclerotherapy 
required 10-15ml of sclerosant, giving more than 
15ml resulted in severe retrosternal pain.  All patients 
had retrosternal pain but this was relieved by 
antispasmodics like buscopan, paracetamol  
antiacids/H2 receptor antagonists. The patients would 
also have odynophagia soon after injection 
sclerotherapy but this would disappear within 2 days 
once the oedema at the injection site regressed. A 
rather severe complication is variceal ulcer, which 
might form at injection site and was observed in most 
cases.  The ulcers would be successfully treated with 
1-week H2receptor antagonists or proton pump 
inhibitors. Oesophageal stricture, which occurs 
within 3 months of sclerotherapy, is a known 
complication of injection sclerotherapy but we did 
not get any cases. We conclude that injection 
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